Abstract
The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts. This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclinical paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alcohol, methamphetamine, and heroin. This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists. Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand. In addition, selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-associated stimuli that play a key role in reinstatement of drug-seeking behavior. These preclinical findings will be discussed in the context of translational research relevant to the design of early clinical trials and hypothesis testing in humans.
Keywords: Addiction, dopamine, D3 receptor, impulse control disorder, selective antagonists
CNS & Neurological Disorders - Drug Targets
Title: Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence
Volume: 7 Issue: 5
Author(s): Christian Heidbreder
Affiliation:
Keywords: Addiction, dopamine, D3 receptor, impulse control disorder, selective antagonists
Abstract: The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts. This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclinical paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alcohol, methamphetamine, and heroin. This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists. Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand. In addition, selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-associated stimuli that play a key role in reinstatement of drug-seeking behavior. These preclinical findings will be discussed in the context of translational research relevant to the design of early clinical trials and hypothesis testing in humans.
Export Options
About this article
Cite this article as:
Heidbreder Christian, Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence, CNS & Neurological Disorders - Drug Targets 2008; 7 (5) . https://dx.doi.org/10.2174/187152708786927822
DOI https://dx.doi.org/10.2174/187152708786927822 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology New Approaches to the Discovery of cdk5 Inhibitors
Current Alzheimer Research Optimisation of [<sup>11</sup>C]Raclopride Production Using a Synthra GPextent System
Current Radiopharmaceuticals Adherence to Antiretroviral Therapy Among Iranian HIV/AIDS Patients
Current Clinical Pharmacology Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets Cellular Mechanisms Underlying the Interaction between Cannabinoid and Opioid System
Current Drug Targets Dantrolene : From Malignant Hyperthermia to Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Role of NPY and Ghrelin in Anorexia Nervosa
Current Pharmaceutical Design Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Role of Mitochondrial Impairment in Alzheimer´s Disease Neurodegeneration: The Tau Connection
Current Neuropharmacology 6-Benzothiazolyl Ureas, Thioureas and Guanidines are Potent Inhibitors of ABAD/17β-HSD10 and Potential Drugs for Alzheimer"s Disease Treatment: Design, Synthesis and in vitro Evaluation
Medicinal Chemistry Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry Application of Chiral α-Monofluorocarbonyl Compounds to Analytical and Medicinal Chemistry
Current Organic Chemistry Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Pharmacology and Drug Discovery for T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Metal Complexes as Chemotherapeutic Agents Against Tropical Diseases: Trypanosomiasis, Malaria and Leishmaniasis
Mini-Reviews in Medicinal Chemistry The Bullying Prevention Plan: An Approach to Youth who Bully Others
Adolescent Psychiatry Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Adulteration Practices of Psychoactive Illicit Drugs: An Updated Review
Current Pharmaceutical Biotechnology